Medical network - on February 17, now is the major pharmaceutical listed companies released when earnings forecast in 2016. As of February 3, 2017, a total of 157 medical listed companies released 2016 annual performance forecast. Company types including pharmaceutical companies, YiXie, medical services and pharmaceutical commercial enterprises.
Described 2016 Chinese pharmaceutical listed companies performance expectations: high growth, and with a sharp change of industrial logic consistent; Staggering growth, was associated with a merger, acquisition and reorganization, and financial and table, but on the main business of the industry as a whole digital growth and two votes or there is a direct correlation.
Source: wide hang seng securities research institute
157 pharmaceutical listed companies, the 78% earnings growth is realized. Earnings growth is more than 100% of 32 (20.38%), the growth rate of 50% ~ 100% at 18 (11.46%), growth rate of 20% ~ 50% of 41 (26.11%), growth rate of 0% ~ 20% of 33 (21.02%).
It is worth noting that achieve earnings growth by more than 20% or even 100% of a big reason is that external m&a restructuring and table. A total of 14 companies through the assets reorganization and profits and table to realize 100% earnings growth. The wide reputation far it may be said "rocket type" growth, up 4727%; And even the slowest growth temmoku pharmaceutical year-on-year growth is still as high as 103% ~ 103%. But after stripping out the, only 17 companies achieve results more than 100% of the ultra-high speed growth, 12 companies achieve performance by 50% ~ 100% growth, 28 companies achieve performance by 20% ~ 50% growth.
In addition to restructure and table, product prices, low base last year or the year profit made by the high-speed growth, many companies in 2016 won the good performance of endogenous growth. Contributing to that growth focused on: the key varieties on the sales volume, prices rise, and internal strict cost control. Dhi sichuan pharmaceutical, yasuhiro miyata pharmaceutical, pharmaceutical group, China method in this column.
In conclusion, in the pharmaceutical sector, the main factors influencing the medicine and performance variation of enterprises for API price increases, this has to do with API price in recent years by industry buzz. There are nine companies benefit from vitamin API products such as price, achieve results more than 100% of high-speed growth. Active pharmaceutical ingredients to the dividends of listed companies considerable rise in price. The fastest growth in wide pharmaceutical year-on-year growth of 593.07% ~ 640.87%, even the slowest growth in the northeast pharmaceutical rose as high as 102.60% ~ 106.50%.
The main factors influencing the Chinese traditional medicine enterprise performance variation for two votes and the channel such as bidding and pricing changes, the challenge for the traditional Chinese medicine enterprises have been reflected in the performance of listed companies. 38 released preliminary results of traditional Chinese medicine have 11 companies in the listed companies performance fell, proportion is as high as 40%.
Medicine in the commercial sector, local leading type medicine circulation enterprises listed, thanks to two votes, such as, improve the industry concentration policy become one of the best kind of earnings growth expectations.
In the company of declining performance, there are 3 companies are greatly influenced by the industry events. Among them, the tiger medicine, bo dhi medicine performance influenced by the "7.22" clinical data verification is huge, and the performance of flying creature affected by shandong vaccine events also showed a sharp dive. |
